Skip to content

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Pfizer logo
PfizerPFE
$90.1B-0.3%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$84.36M+779%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$218.73M+875%
Nuvation Bio logo
Nuvation BioNUVB
$319.56M-23.8%
Immunome logo
ImmunomeIMNM
$588.69M+91.7%

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s total equity?
Nuvectis Pharma, Inc. (NVCT) reported total equity of $14.22M in Q1 2026.
How has Nuvectis Pharma, Inc.'s total equity changed year-over-year?
Nuvectis Pharma, Inc.'s total equity decreased by 32.1% year-over-year, from $20.95M to $14.22M.
What is the long-term trend for Nuvectis Pharma, Inc.'s total equity?
Over 5 years (2020 to 2025), Nuvectis Pharma, Inc.'s total equity has grown at a 349.8% compound annual growth rate (CAGR), from -$10K to $18.41M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.